Compare MX & CNTN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MX | CNTN |
|---|---|---|
| Founded | 2003 | 2017 |
| Country | South Korea | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 179.7M | 178.5M |
| IPO Year | 2007 | 2021 |
| Metric | MX | CNTN |
|---|---|---|
| Price | $2.38 | $1.94 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 758.5K | 685.7K |
| Earning Date | 11-04-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 43.06 | ★ 88.10 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $178,860,000.00 | N/A |
| Revenue This Year | $5.39 | N/A |
| Revenue Next Year | $6.37 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.18 | $1.66 |
| 52 Week High | $9.86 | $5.27 |
| Indicator | MX | CNTN |
|---|---|---|
| Relative Strength Index (RSI) | 34.33 | 46.24 |
| Support Level | N/A | $1.71 |
| Resistance Level | $3.06 | $2.40 |
| Average True Range (ATR) | 0.13 | 0.14 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 3.63 | 55.86 |
MagnaChip Semiconductor Corp designs and manufactures analog and mixed-signal semiconductor platform solutions for communications, Internet of Things applications, consumer, industrial and automotive applications. The company's product portfolio consists of large display solutions, mobile display solutions, sensor solutions, LED solutions, mobile solutions, and power conversions. The Company operates within a single operating segment, Power Solutions business. The company operates in Korea, Asia Pacific (other than Korea), United States and Europe.
Canton Strategic Holdings Inc is engaged in activities related to Canton Network, including the use of Canton Coin, to support blockchain-based infrastructure and the digitization of financial market processes. The company operates in two reportable segments: digital asset treasury and clinical stage bio-technology. Its flagship clinical asset, GV104, is being developed for a specific indication for respiratory and/or nervous system depression in military personnel and chemical incident responders. The expanded pipeline includes other indications for GV104 and GV023, an approach to autoimmune diseases as well as an early-stage multispecific biologic platform.